AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Benitec Biopharma Inc.
Video analysis: BNTC
All videosNo video analysis for this stock yet. Request one from our team.
News: BNTC
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October Additional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking presentation at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany taking place on October 27-30, 2026 Well-capitalized with cash, as of June 30, 2026, of approximately $180 million. HAYWARD, Calif.
AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC
AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ: BNTC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 187,977 shares of the biotechnology company's stock, valued at approximately $2,515,000. AWM Investment Company Inc. owned about 0.55% of
